Streetbeat News

Earnings

MRCC

Monroe Cap (NASDAQ:MRCC) reported Q4 2023 adjusted EPS of $0.26, missing the $0.28 estimate, and sales of $15.503M, below the $16.557M estimate. This represents a 2.24% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 8:28 pm

CASY

Casey's General Stores (CASY) reported Q3 2024 earnings of $2.33 per share, beating the $2.15 estimate. However, sales of $3.329B missed the $3.511B estimate, marking a 0.12% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 8:27 pm

ASAN

Asana, Inc. (NYSE:ASAN) reported Q4 financial results, surpassing analyst expectations with a quarterly loss of 4 cents per share and sales of $171.1 million. The company also saw significant customer growth and expects to be free cash flow positive by year-end. For FY 2025, Asana anticipates revenues between $716 million and $722 million, slightly below the $724.75 million estimate.

Portfolio Pulse from Erica Kollmann

March 11, 2024 | 8:27 pm

PACK

Ranpak Holdings (PACK) reported Q4 2023 earnings with a GAAP EPS of $(0.11), missing the $(0.03) estimate by 266.67%. However, their sales of $90.4M exceeded the $87.042M estimate by 3.86%, marking a 13.85% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 8:25 pm

CPHC

Canterbury Park Holding (NASDAQ:CPHC) reported a Q4 EPS of $0.27, up 22.73% from $0.22 YoY. However, sales decreased by 4.51% to $12.53M from $13.12M YoY.

Portfolio Pulse from Happy Mohamed

March 11, 2024 | 8:25 pm

LFMD

LifeMD projects Q1 revenue to be between $42M-$43M, closely aligning with the $42.54M estimate. For FY24, the company anticipates over $200M in revenue, surpassing the $191.52M estimate and adjusting its prior forecast from $195M-$205M.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 8:25 pm

MBIO

Mustang Bio reported a FY23 EPS of $(6.00), an improvement from $(10.09) YoY, alongside a significant decrease in cash and cash equivalents from $76.7 million to $7.0 million. The company made a $30.4 million payment to terminate existing debt and sold assets to uBriGene for $6 million upfront with a potential additional $5 million contingent payment. Research and development expenses decreased to $40.5 million from $62.5 million in 2022. Mustang Bio's lead clinical candidate, MB-106, showed a 100% overall response rate in Phase 1/2 clinical trials for certain hematologic malignancies. The FDA granted Orphan Drug Designation to MB-106 for WM treatment. Additionally, Mustang announced the FDA's acceptance of an IND for a Phase 1 trial of MB-109 for recurrent GBM and high-grade astrocytoma.

Portfolio Pulse from Happy Mohamed

March 11, 2024 | 8:24 pm

AVO

Mission Produce (NASDAQ:AVO) reported Q1 2024 adjusted EPS of $0.09, surpassing the $(0.07) estimate, with sales of $258.7M exceeding the $210.75M forecast, marking a 21.17% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 8:24 pm

ORIC

ORIC Pharmaceuticals reported its Q4 earnings with a loss of $(0.49) per share, meeting the analyst consensus estimate. This represents a 5.77% improvement over the previous year's loss of $(0.52) per share.

Portfolio Pulse from Happy Mohamed

March 11, 2024 | 8:22 pm

CRBU

Caribou Biosciences (NASDAQ:CRBU) reported Q4 earnings with a loss of $(0.39) per share, missing the $(0.37) estimate, and sales of $3.56M, missing the $4.61M estimate. This represents an 11.36% increase in losses per share but a 3.63% decrease in sales compared to the same period last year.

Portfolio Pulse from Happy Mohamed

March 11, 2024 | 8:22 pm